Treatment of Yeast Infection in Patients Taking Plavix (Clopidogrel)

Rationale for Avoiding Oral Fluconazole

The American College of Physicians and Infectious Diseases specialists recommend avoiding oral fluconazole in patients taking Plavix due to its moderate-to-strong CYP2C19 inhibition, which can reduce the antiplatelet effect of clopidogrel and increase cardiovascular risk 1

For uncomplicated vulvovaginal candidiasis, the Infectious Diseases Society of America recommends topical antifungal agents, such as clotrimazole, miconazole, or terconazole, as first-line therapy to avoid drug interactions with clopidogrel, with clinical cure rates of 92-99% 1
For severe or complicated vulvovaginal candidiasis, a brief consultation with cardiology regarding temporary interruption or bridging of antiplatelet therapy may be necessary if oral fluconazole is absolutely necessary, or extended topical therapy (7-14 days) can be used as an alternative approach 1

The American Heart Association and Infectious Diseases specialists advise against prescribing oral fluconazole without considering the Plavix interaction, as this could lead to stent thrombosis or acute coronary events in high-risk patients 1

For invasive candidiasis or esophageal candidiasis requiring systemic treatment, the Infectious Diseases Society of America recommends echinocandins (caspofungin, micafungin, anidulafungin) as the preferred treatment option due to their lack of interaction with clopidogrel 1, 2
Amphotericin B formulations are also recommended as an alternative option due to their lack of CYP interactions, although they have greater toxicity 1, 2